Analysis: HPLC / LC-MS
Delivery: Cold-chain
Traceability: COA per batch

Sermorelin + GHRP-6

10 mg / pen

The most classical GH axis pairing — GHRH analogue with ghrelin receptor compound — research pen

Batch reference: FR-SG6-2507
Retest date: July 2028

1 box · 10 mg per pen

$139

Select pack

1 box$139Single pack3 boxes$317Save 24%10 boxes$973Save 30%

Packs

I confirm that Sermorelin + GHRP-6 10 mg is purchased strictly for laboratory research use, is not for human or veterinary consumption, and that I am a qualified researcher aged 21 or older.

Ships in 24hDiscreet packaging

Sermorelin + GHRP-6 is a dual-peptide research formulation combining a GHRH-receptor agonist with a ghrelin-receptor agonist. Sermorelin (5mg) activates GHRH receptors on pituitary somatotrophs via cAMP. GHRP-6 (5mg) activates GHS-R1a through G-protein and calcium signalling. Together they provide a model for investigating complementary endocrine pathways with documented synergistic growth hormone responses. GHRP-6 additionally contributes appetite-related hypothalamic signalling. Each component is assayed independently on the Certificate of Analysis. FAB Research supplies this blend as a 10mg pre-filled metered research pen.

Blend composition

Sermorelin (5 mg)
GHRP-6 (5 mg)

Each component is assayed separately on the Certificate of Analysis.

Sermorelin and GHRP-6 act through distinct receptor systems. GHRH receptor activation involves Gs protein, cAMP elevation and calcium-dependent growth hormone release, modulated by somatostatin tone. GHS-R1a activation involves phospholipase C and intracellular calcium mobilisation. The two pathways converge on pituitary somatotrophs, producing synergistic release well-documented in combination pharmacology literature. GHRP-6 additionally activates hypothalamic ghrelin circuits and has been investigated for cytoprotective effects in cardiac and gastric models independent of growth hormone release.

A historically important pairing with strong individual compound literature. Combination pharmacology studies documented synergistic growth hormone release greater than either compound alone. The selectivity profile differs from Sermorelin + Ipamorelin: GHRP-6 produces more pronounced cortisol and prolactin responses, making this combination relevant to studies where the full endocrine consequences of ghrelin receptor activation are being investigated. Note: listed by anti-doping authorities.

2.5 mg per application (1.25 mg Sermorelin + 1.25 mg GHRP-6 per dose)
4 doses per pen (10 mg total)
Dual-pathway combination: GHRH-R (Sermorelin) + GHS-R1a (GHRP-6) co-stimulation
Each component independently assayed on the Certificate of Analysis

Storage: Store refrigerated at 2–8 °C in the original sealed box. Do not freeze. Protect from light.

For in-vitro laboratory and preclinical research only — not for human or animal administration
GHRP-6 component is listed by WADA — detection is established
Dual-pathway GH secretagogue design: synergistic release greater than either component individually — well documented in combination pharmacology literature
GHRP-6 appetite stimulation, cortisol and prolactin elevation will be present in this combination — account for in study designs involving food intake, HPA axis or prolactin endpoints

Combined effects from both components
Pronounced appetite / hunger stimulation (GHRP-6 component — hypothalamic GHS-R1a mechanism)
Flushing, headache (both components contribute)
Transient water retention
Transient cortisol and prolactin elevation (GHRP-6 component — intermediate level)
Injection site reactions
Anti-doping listed (GHRP-6 component): detection established

Effects listed are observations from published research literature and are not predictions for any specific use. All FAB Research products are for in-vitro laboratory research — not for human or animal administration.